Bayer AG · XETR:BAYN

Bayer — 40th Annual J.P. Morgan Healthcare Conference 2022

12 slides from Bayer's conference presentation, Jan 10, 2022

  1. Slide 1: J.P. Morgan Healthcare Conference

    40th Annual J.P. Morgan Healthcare Conference January 10-13, 2022 /////////// Stefan Oelrich Member of the Board of Management of Bayer AG President of the Pharmaceuticals Division 1 /// JP Morgan Healthcare Conference /// January 10-13, 2022

  2. Slide 2: Cautionary statements regarding forward-looking information

    Cautionary statements regarding forward-looking information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the ac

  3. Slide 3: Bayer Pharma is delivering on strategic growth agenda

    Bayer Pharma is delivering on strategic growth agenda 2018 - 2021 2021+ Capitalize on full Strengthened patent situation in EU commercial potential Life Cycle management Deliver on new >1bn sales Elinzanetant blockbusters ARASENS data FXI(a) portfolio Strengthen New leadership team innovation engine

  4. Slide 4: On track to deliver on raised top-line guidance, while keeping attractive margin

    On track to deliver on raised top-line guidance, while keeping attractive margin amid continued investments in growth Year-on-year sales growth (cpa) +7% Top-line guidance for FY 2021 raised Q1: +0% ~6% in August reflecting continued positive momentum Strong sales recovery Q2 onwards ~4% after 2020

  5. Slide 5: Capturing the full commercial potential of market leading therapies

    Capturing the full commercial potential of market leading therapies +7.7% +20.6% yoy in 9M 2021 yoy in 9M 2021 New indications & label updates in 2021 2 Phase III studies with high-dose formulation (initiated 2020) Pediatric VTE: approved in EU, Japan, Canada PHOTON (DME) (EINSTEIN Jr) and the US (E

  6. Slide 6: Nubeqa to become foundational drug across patient spectrum in prostate cancer

    Nubeqa to become foundational drug across patient spectrum in prostate cancer – further data to be released in Feb 2022 Highly differentiated ‘Survival without compromise’, giving NUBEQA the potential Strong efficacy tolerability profile to be used across the entire spectrum of PC nmCRPC mHSPC Adjuv

  7. Slide 7: Kerendia a game changer for CKD and type 2 diabetes patients

    Kerendia a game changer for CKD and type 2 diabetes patients Next milestone in renal disease treatment, continuing our RAAS-centric treatment history Largest clinical program Successful launch trajectory Entresto with unparalleled data1 2020 Weekly TRx (US) Novel MOA intensifies 3.000 RAAS inhibitio

  8. Slide 8: Novel drug candidates in Women's Health and Cardiovascular Diseases

    Novel drug candidates in Women’s Health and Cardiovascular Diseases to drive mid-term growth Transformative approach for Next class of anticoagulation drug menopause syndromes candidates with disruptive potential Elinzanetant (2025) World leading factor XI program (2026) Addressing menopause syndrom

  9. Slide 9: Advancing leading CGT platform with strong clinical pipeline

    Advancing leading CGT platform with strong clinical pipeline Example: Two-pronged approach to deliver transformative therapies to treat Parkinson’s Diverse tech platforms and capabilities AAV platform (AskBio and Successful administration Bayer established) of first dose of DA011 to a BlueRock´s iPS

  10. Slide 10: Our innovation engine is delivering

    Our innovation engine is delivering 2 Committed and experienced External new leadership team Innovation 1 3 Advancing leading cell and Internal Platform gene therapy business Innovation Companies World leading science added 1 2 3 through new platforms Global R&D Collaborations, CGT SMOL organization

  11. Slide 11: Bayer Pharma: Shaping the foundation for long-term growth

    Bayer Pharma: Shaping the foundation for long-term growth Fully capturing Building new Innovation engine is Maintain attractive commercial value of blockbusters with delivering across all margins amid market leading therapeutic stages of clinical investments in therapies breakthrough development gro

  12. Slide 12: J.P. Morgan Healthcare Conference

    40th Annual J.P. Morgan Healthcare Conference January 10-13, 2022 /////////// Stefan Oelrich Member of the Board of Management of Bayer AG President of the Pharmaceuticals Division 12 /// JP Morgan Healthcare Conference /// January 10-13, 2022

Bayer — 40th Annual J.P. Morgan Healthcare Conference 2022 on 6ix